Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

High Dose Trial in COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-08-10

Last Posted Date: 2013-10-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 78

Registration Number: NCT00128440

Locations: 🇺🇸
Boehringer Ingelheim Investigational Site, Tacoma, Washington, United States

Dose Finding Study in COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-07-22

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 389

Registration Number: NCT00122434

Locations: 🇺🇸
McGuire VA, Fredericksburg, Virginia, United States
🇳🇱
Academisch Ziekenhuis Nijmegen St. Radbout, Nijmegen, Netherlands
🇳🇱
Gelre Ziekenhuizen, Zutphen, Netherlands

and more 28 locations

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-04-01

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 166

Registration Number: NCT00106821

Locations: 🇺🇸
LSU MC-Sheveport, Shreveport, Louisiana, United States
🇺🇸
VAMC Houston, Houston, Texas, United States
🇺🇸
Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States

and more 13 locations

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Conditions: HIV Infections

First Posted Date: 2004-12-01

Last Posted Date: 2016-11-30

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT00097799

Locations: 🇺🇸
1182.70.066, Los Angeles, California, United States
🇺🇸
1182.70.174, Macon, Georgia, United States
🇺🇸
1182.70.071, Los Angeles, California, United States

and more 112 locations

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2004-11-15

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 113

Registration Number: NCT00096616

Locations: 🇺🇸
Ben Taul General Hospital, Houston, Texas, United States
🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
620 South 20th Street, NHB 104, Birmingham, Alabama, United States

and more 15 locations

Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 3

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-07-16

Last Posted Date: 2010-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 600

Registration Number: NCT00003328

Locations: 🇺🇸
Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States
🇺🇸
Health Advance Institute, Peoria, Illinois, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 1 locations

Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: TPV oral solution
Drug: RTV oral solution

First Posted Date: 2004-02-10

Last Posted Date: 2014-05-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 115

Registration Number: NCT00076999

Locations: 🇨🇦
1182.14.11002 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇺🇸
1182.14.00003 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸
1182.14.00010 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States

and more 27 locations

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

Conditions: HIV Infections

First Posted Date: 2003-06-12

Last Posted Date: 2016-11-30

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT00062660

Locations: 🇺🇸
1182.58.20 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
1182.58.18 University of Texas Southwest Medical Center at Dallas, Dallas, Texas, United States
🇦🇺
1182.58.61012 Bigge Park Centre, Liverpool, New South Wales, Australia

and more 143 locations

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Phase 2

Terminated

Conditions: Cystic Fibrosis

First Posted Date: 2003-05-14

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 420

Registration Number: NCT00060801

Locations: 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University-St. Louis Children's Hospital, St. Louis, Missouri, United States
🇺🇸
Children's Hospital Medical Center of Akron, Akron, Ohio, United States

and more 32 locations

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2003-03-21

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 328

Registration Number: NCT00056641

Locations: 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇩🇪
Boehringer Ingelheim Investigational Site, Stuttgart, Germany

and more 78 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy